← Issue №20/ week of Nov 15, 2026/Hepatology

Efficacy and safety of dabigatran in cirrhosis with chronic portal vein thrombosis: A randomized, placebo-controlled double-blind trial (DAB-PVT).

From GI Signals issue №20: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology rct · n=84 · Nov 12, 2026 · Am J Gastro · IF 9.8

Efficacy and safety of dabigatran in cirrhosis with chronic portal vein thrombosis: A randomized, placebo-controlled double-blind trial (DAB-PVT).

New evidencecirrhosisportal hypertensionvariceal bleeding
Clinical takeawayDabigatran 150 mg twice daily can be considered for recanalizing chronic PVT in Child-Pugh A/B cirrhosis on the strength of this placebo-controlled trial (42 patients per arm); the fewer bleeding events and better CTP and ALBI scores are exploratory.
What it foundComplete recanalization at 12 months: 27/42 (64.3%) with dabigatran 150 mg twice daily vs 9/42 (21.4%) with placebo (p<0.001). Variceal bleeding episodes were fewer (3 vs 12; p=0.008), a clinical-event difference the authors call exploratory.
ContextDOACs are emerging options for PVT in cirrhosis, with uncertain safety and efficacy. Patients had a median CTP score of 8 and 45.2% had prior variceal bleeding; MELD trajectories did not differ between groups.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Meena BL … Sarin SK · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
← Read the whole of issue №20 Every paper GI Signals surfaces gets a page like this one. All issues